Abstract: Disclosed herein are methods of treating a patient having an intestinal disorder, the methods comprising: administering to a patient in need thereof a pharmaceutical composition comprising a hydrate or solvate form of rifaximin in polymorphic form ?, alone or in a mixture with other crystalline, hydrate, solvate or amorphous forms of rifaximin, in gastroresistant microgranules, wherein the rifaximin is administered at a dose of at least 800 mg per day for a period of at least 7 days.

Abstract: The present invention describes liquid compositions comprising pharmaceutically active principles, like scarcely water-soluble, nonsteroidal anti-inflammatory drugs, in particular, but not exclusively, flurbiprofen (FP), processes for their manufacture and their therapeutic use. The liquid compositions comprising FP in association with natural polymers, like xyloglucans (XG), and pharmaceutically acceptable excipients like glycerol, are suitable to be used for pharmaceutical uses and are characterized by good tolerability, therapeutic efficacy, stability and palatability.

Abstract: A continuous flow centrifuge system is provided. The system includes a rotor, a stator, a stator housing, upper and lower bearing plates, upper and lower bearings, first and second snap rings, and lip seal. The upper bearing rotatably secures a shaft of the rotor in the upper bearing plate. The first snap ring secures the upper bearing to the rotor shaft. The lip seal is over the upper bearing and forms a rotatable seal with the upper bearing plate. The second snap ring secures the lip seal to an inner diameter of the upper bearing plate. The upper and lower bearing plates are secured to the stator housing so that the rotor is operatively aligned with the stator.

Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

Abstract: A device for positioning a component thereof along x- and y-axes of the device is provided. The device includes first and second motors, a carriage containing the component to be positioned, a lead screw to position the carriage along a first axis of the device, and a keyed shaft to position component to be positioned along a second axis of the device. The first motor drives the lead screw and the second motor drives the flatted shaft. In some embodiments described herein, the flatted shaft turns a first pulley, which is connected to a second pulley by a belt. The component to be positioned is attached to the belt and moves along a second axis of the device as the belt moves.

Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.

Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

Abstract: Polyols stabilize polymorphous form of rifaximin, in particular the ? form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph ? is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described.

Abstract: An automated liquid collection workstation is provided. The workstation includes a processor, a peristaltic pump, a valve actuator, and an algorithm. The peristaltic pump and the valve actuator are in electrical communication with the processor. The valve actuator can move a plurality of valves, when disposed therein, among an off position, a flush position, and a collection position. The algorithm is resident on the processor and is configured to: move all of the valves to the off position and place the pump in an off state when no sampling or flushing is required, move all of the valves to the flush position and place the pump in an on state for a predetermined flush time period when flushing is required, and move a respective one of the valves to the collection position, move any of the valves upstream of the respective valve to the flush position, and place the pump to the on state for a predetermined collection time period when collection is required.

Abstract: An automated sample collection workstation is provided. The workstation includes a processor, a peristaltic pump, a valve actuator, and an algorithm. The peristaltic pump and the valve actuator are in electrical communication with the processor. The valve actuator can move a plurality of valves, when disposed therein, among an off position, a flush position, and a sample position. The algorithm is resident on the processor and is configured to: move all of the valves to the off position and place the pump in an off state when no sampling or flushing is required, move all of the valves to the flush position and place the pump in an on state for a predetermined flush time period when flushing is required, and move a respective one of the valves to the sample position, move any of the valves upstream of the respective valve to the flush position, and place the pump to the on state for a predetermined sample time period when a sample is required.

Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

Abstract: A continuous flow centrifuge system is provided. The system includes a rotor, a stator, a stator housing, upper and lower bearing plates, upper and lower bearings, first and second snap rings, and lip seal. The upper bearing rotatably secures a shaft of the rotor in the upper bearing plate. The first snap ring secures the upper bearing to the rotor shaft. The lip seal is over the upper bearing and forms a rotatable seal with the upper bearing plate. The second snap ring secures the lip seal to an inner diameter of the upper bearing plate. The upper and lower bearing plates are secured to the stator housing so that the rotor is operatively aligned with the stator.

Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.

Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

Abstract: Object of the invention are mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients.

Abstract: A system for separating a sample and collecting the separated sample. The system includes an ultracentrifuge having a cylindrical rotor. The system includes a gradient delivery assembly for delivering a gradient solution to the ultracentrifuge rotor, and a sample delivery assembly for delivering the solution containing the sample to the ultracentrifuge rotor. The system includes a fraction collection assembly for collecting discrete volumes of the separated sample. The system includes a processor for controlling operation of the ultracentrifuge, as well as the gradient delivery assembly, the sample delivery assembly, and/or the fraction collection assembly.

Abstract: The present invention relates to Rifaximin polymorphic forms ?, ? and ?, to their use in medicinal preparations for the oral or topical route and to therapeutic methods using them.

Abstract: Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin ? are described, along with the production of medicinal preparations containing rifaximin for oral and topical use.

Abstract: A system for separating a sample and collecting the separated sample. The system includes an ultracentrifuge having a cylindrical rotor. The system includes a gradient delivery assembly for delivering a gradient solution to the ultracentrifuge rotor, and a sample delivery assembly for delivering the solution containing the sample to the ultracentrifuge rotor. The system includes a fraction collection assembly for collecting discrete volumes of the separated sample. The system includes a processor for controlling operation of the ultracentrifuge, as well as the gradient delivery assembly, the sample delivery assembly, and/or the fraction collection assembly.